Serum Beta 2-Microglobulin/Cystatin C Index: A Useful Biomarker in Lupus Nephritis?

Marcus Vinicius Madureira Silva a  Grace T. Moscoso-Solorzano a, b  Sonia K. Nishida a  Gianna Mastroianni-Kirsztajn a

a Glomerulopathy Section, Division of Nephrology, Federal University of São Paulo, São Paulo, Brazil; b Servicio Murciano de Salud, Area III, Lorca, Spain

Key Words
Beta 2-microglobulin • Cystatin C • Systemic lupus erythematosus • Disease activity • Relapse • Biomarker

Abstract
Background: Systemic lupus erythematosus (SLE) is a chronic multisystem autoimmune disease with frequent flares. Our aim was to evaluate the beta 2-microglobulin/cystatin C (β2M/CysC) index versus other markers as a predictor factor for assessment of SLE reactivation. Methods: We prospectively analyzed 42 patients with lupus nephritis. Disease activity was classified using SLEDAI-2K and BILAG. Routine renal function and laboratory markers of SLE activity were performed, as well as serum β2M (Sβ2M)/serum CysC (SCysC) and Sβ2M/serum creatinine (SCreat) indexes determinations. Results: The 42 enrolled patients had a mean age of 37.7 ± 13.1 years, 88% were female and 67% Caucasians; mean estimated glomerular filtration rate was 61.9 ± 20.0 ml/min/1.73 m². There was a strong correlation between SCreat versus SCysC (r = 0.887), SCreat versus Sβ2M (r = 0.865), and SCysC versus Sβ2M (r = 0.880). Multivariate analysis showed that the Sβ2M/SCreat index is a prognostic factor predicting active lupus nephritis. Conclusion: As SCysC is a good marker of renal function, it would be expected that the Sβ2M/SCysC index could be a better indicator of renal activity than Sβ2M/SCreat, but in the present study it did not add relevant clinical information in the assessment of renal activity in SLE.

Copyright © 2012 S. Karger AG, Basel
**Introduction**

Systemic lupus erythematosus (SLE) is a chronic multisystem autoimmune disease with frequent flares, often requiring hospitalization and immunosuppressive therapy [1–5]. Several immunologic markers are used in laboratory monitoring of disease activity in SLE patients, and some of them are components of disease activity indexes such as SLE Disease Activity Index (SLEDAI), Systemic Lupus Activity Measure (SLAM) and British Isles Lupus Assessment Group (BILAG) [6–9]. Considering the morbidity associated with SLE and particularly with lupus nephritis, it is important to identify sensitive and specific biomarkers of disease activity which could aid in the detection and assessment of flares and degree of disease activity [10, 11].

Beta 2-microglobulin (β2M) is a low-molecular-weight protein (11 kDa) mainly released by activated lymphocytes. Daily synthesis of β2M ranges from 50 to 200 mg with an estimated half-life of approximately 2 h [12–14]. High levels of serum β2M (Sβ2M) were described in rheumatoid arthritis, Sjögren’s syndrome and SLE. β2M is catabolized by the kidneys, and there is a linear inverse correlation between levels of Sβ2M and glomerular filtration rate (GFR); its elimination is constant in normal people when its production is also constant [15]. Approximately 99.5% of β2M is freely filtrated by glomeruli and reabsorbed in renal proximal tubules. In the presence of renal dysfunction, β2M serum levels are increased when compared to those of patients with normal renal function [12–16].

Some studies have previously failed to show a role for Sβ2M as a biomarker in SLE activity due mainly to its limited use in patients with renal involvement characterized by a reduction of the GFR [12–19].

On the other hand, routinely used endogenous markers, such as serum urea and creatinine (SCreat), have several limitations [20, 21]. The lack of an ideal index of renal function requires a search for new substances [22]. Serum cystatin C (SCysC) has been proposed as a promising marker of GFR and it is seen as equivalent or even superior to SCreat [17–23]. In addition SCysC has been recently recognized as a marker of inflammation and cardiovascular mortality [20–26].

In order to reduce possible misinterpretation in the assessment of Sβ2M in SLE patients with disease activity and renal dysfunction, we have proposed to correct Sβ2M levels through an index where a marker of kidney function (such as SCysC or SCreat) is the denominator. We hypothesize that the Sβ2M/SCysC index could be a more accurate biomarker of SLE activity in cases of reduced GFR than Sβ2M.

**Patients and Methods**

**Study Population**

Forty-two patients with SLE whose diagnosis was established by the presence of at least four criteria of ARA [1–4] were prospectively enrolled. These patients were followed in the Glomerulopathy Section (Nephrology Division) of the Federal University of São Paulo. All of them had renal involvement during the course of SLE. Those patients with a previous renal biopsy were classified according to WHO lupus nephritis classification [26].

The study was approved by the Ethics Committee and the patients were included in the study after giving their informed consent. At some time during the course of SLE, all of them have used corticosteroids, and during this study the doses were defined according to clinical status and the presence of lupus activity evidence, which was evaluated by the application of SLEDAI-2K criteria [1–3].
In the evaluation of all patients, SCysC, Sβ2M, urine retinol-binding protein (urRBP), clinical history, physical examination and routine laboratory exams were performed, as well as the determination of the laboratory items necessary to calculate SLEDAI-2K and BILAG indexes.

The exclusion criteria corresponded to concurrent lymphoproliferative or autoimmune diseases (as rheumatoid arthritis, ankylosing spondylitis and Crohn disease), chronic infectious diseases (such as AIDS), active infections (such as tuberculosis and viral hepatitis), chronic kidney disease stage 5, renal transplantation, malignances and concurrent non-lupus-related glomerulopathies.

Many therapies were used to control SLE and lupus nephritis manifestations, including corticosteroids, azathioprine, cyclosporine, cyclophosphamide and antimalarials. Statins, angiotensin-converting enzyme inhibitors (ACEi) and angiotensin II receptor antagonists (ARA II) were also frequently administered. In addition, no patient used nonsteroidal anti-inflammatory drugs (NSAID) during the period of follow-up, in order to reduce nephrotoxicity risk.

SCreat levels were used as reference to establish whether SCysC levels could be attributed only to renal function variation.

Criteria of SLE Activity

SLE activity was determined using SLEDAI-2K and BILAG criteria. By the SLEDAI-2K, activity manifestations until ten days before medical appointment had a score equal or higher than six [7, 8]. BILAG A and B corresponded to the presence of disease activity, and BILAG C, D and E to the absence [9] until four weeks before medical visit.

Methods

Sβ2M was determined with a one-step immunoenzymometric assay developed in house. RBP levels were measured in urine samples as described by Pereira et al. [27]. Serum CysC was determined with an in-house developed assay using an automated microsphere-based flow cytometric methodology (Luminex, Austin, Tex., USA) [29]. The results were expressed in mg/l, using as reference a standard curve with calibrators from the Cystatin C PET Kit by Dako. The values obtained were comparable to those of the commercial assay kit N Latex Cystatin C by Dade Behring (r² = 0.884) and Cystatin C PET Kit by Dako (r² = 0.814). In a population of patients and normal individuals (n = 156) we studied measurements of GFR obtained by the iohexol clearance and CysC, and we obtained a good correlation coefficient between them (r² = 0.821). There was no difference between means in males and females (t test, p = 0.844). The range of CysC was 0.40–0.91 mg/l, and the reference interval of normality (mean ± 2 SD) was 0.38–0.86 mg/l, similar to that observed in other studies [28, 29].

Serum creatinine was determined by an automated method based on the alkaline picrate reaction, in a Hitachi 912 (Roche) chemistry analyzer and the results were expressed as mg/dl. Estimated GFR (eGFR) was determined by the 4-variable MDRD formula [30].

Statistical Analysis

Continuous variables were presented as mean ± SD. For comparison among sample means, Student’s t test, ANOVA or Kruskal-Wallis tests (followed by Tukey multiple comparison test) were performed. The significance level was set at p ≤ 0.05. The correlation of SLEDAI-2K and BILAG with anti-dsDNA, C3, C4, Sβ2M/SCysC, Sβ2M/SCreat and urRBP were evaluated by Pearson/Spearman correlation test. The strength of the correlation was defined as per Cohen et al.: strong: r > 0.5, moderate: r ≥ 0.3 and r < 0.5, weak: r ≥ 0.1 and r < 0.3, or absent r < 0.1. The sensitivity/specificity indexes and receiver operating characteristic (ROC) curve analysis were used to discriminate the best value for a positive test to
determine lupus nephritis activity (using SLEDAI-2K score and Sβ2M/SCreat and Sβ2M/SCysC) (see table 1). Multiple linear regression analysis was used to evaluate the association between SLEDAI-2K score and Sβ2M/SCysC index after adjusting for age and sex. We used Stata statistical software (SPSS) 12.0 for all statistical analyses (Stata Corporation, Tex., USA).

**Results**

Demographic Analyses of the Enrolled Population

The mean age of the patients was 37.1 ± 13.1 years (18–78); 37 (88%) of them were females, 67% Caucasians, 19% mulattos and 14% Afro-descendants. Mean duration of SLE diagnosis was 9.0 ± 6.5 years (0.1–26.0). Mean GFR measured by the MDRD formula was 61.9 ± 20.0 ml/min. All patients had used corticosteroids before inclusion in this study as well as during the follow-up according to their global clinical situation and presence or not of SLE activity. Seventy-seven percent of the patients had a renal biopsy, and 54.5% were categorized as class IV (table 2).

Patients who presented with a higher SLEDAI-2K score received a significantly higher dose of corticosteroid or at least there was a tendency to this behavior when considered all groups of doses (data not shown).

Mean Sβ2M levels in lupus nephritis was 2.60 ± 1.50 mg/l. Mean SCreat was 1.20 ± 0.60 mg/dl and SCysC was 1.26 ± 0.78 mg/l. Mean Sβ2M/SCreat and Sβ2M/SCysC were

| Table 1. The sensitivity/specificity indexes and ROC curve analysis for Sβ2M/SCreat and Sβ2M/SCysC |
|---------------------------------|---------------------------------|----------------|----------------|
|                                | Sensitivity | Specificity | TPV        | FPV        |
| Sβ2M/SCreat*                  | SLEDAI-2K  | 52.2%      | 66.7%      | 54.2%      |
| Sβ2M/SCysC**                  | SLEDAI-2K  | 52.2%      | 57.9%      | 60.0%      |

* The value for the area under the ROC curve for Sβ2M/SCreat = 0.27. ** The value for the area under the ROC curve for Sβ2M/SCysC = 2.85. TPV = True positive value; FPV = false positive value.

| Table 2. Demographic, laboratory, clinical and histological characteristics of lupus nephritis patients |
|---------------------------------|---------------------------------|----------------|----------------|
| Characteristics (n = 42)        | Range                           |
| Age, years                     | 37.2 ± 13.1*                    | 18–78          |
| Gender (male/female)           | 5/37                            |
| Race (Caucasian/mulatto/Afro-descendant) | 28/8/6                      |
| Hypertension                   | 26                              |
| Diabetes mellitus              | 3                               |
| Tobacco use                    | 1                               |
| Renal biopsy (class III/IV/V/VI) | 3/18/11/1                      |
| Serum creatinine, mg/dl        | 1.20 ± 0.62*                    | 0.70–4.30      |
| Serum cystatin C, mg/l         | 1.26 ± 0.78*                    | 0.45–4.86      |
| eGFR (MDRD), ml/min/1.73 m²    | 61.9 ± 20.0*                    | 11.4–101.0     |

* Mean ± SD.
0.23 ± 0.07 and 2.02 ± 0.59, respectively. Mean urRBP level was 0.54 ± 0.62 mg/l. Correlation coefficients were: SCysC versus SCreat, \( r = 0.900 \), 1/SCreat versus eGFR (MDRD), \( r = 0.949 \), 1/SCysC versus eGFR (MDRD), \( r = 0.716 \). Correlation between the studied indexes (Sβ2M/SCreat vs. Sβ2M/SCysC) was moderate (\( r = 0.571 \)).

**Correlation between Disease Activity and Serum Levels of β2M and β2M/CysC**

Sβ2M showed a stronger correlation with SLEDAI-2K (\( r = 0.660, p = 0.000 \)) than Sβ2M/SCysC (\( r = 0.180, p = 0.140 \)). Using as reference the SLEDAI-2K, the Sβ2M/SCreat index was only able to distinguish presence versus absence of activity (\( r = 0.589, p = 0.00 \)). dsDNA and C4 showed a weak correlation with SLEDAI-2K (\( r = 0.133, p = 0.580 \)), while urRBP showed a moderate correlation (\( r = 0.489, p = 0.009 \)). Correlation coefficients of Sβ2M/SCreat and Sβ2M/SCysC were both weak considering renal criteria of BILAG, as well as C3 and C4 levels, tests classically utilized in the monitoring of SLE activity.

In a multivariate analysis, using multiple linear regression model, predictive factors for SLE activity (using SLEDAI-2K score) were: Sβ2M (OR = 1.6, 95% CI: 0.26–2.94, \( p < 0.21 \)), Sβ2M/SCreat (OR = 4.0, 95% CI: 1.88–6.21, \( p = 0.001 \)), urRBP (OR = 1.4, 95% CI: 0.39–3.00, \( p < 0.50 \)). Sβ2M/SCysC, C4, C3 and dsDNA (\( p = 0.119 \)) did not have statistical association with these activity criteria (SLEDAI-2K score). The odds ratios (initial multiple linear regression model) for those were: Sβ2M/SCysC (OR = 0.431, 95% CI: –2.066 to 2.938, \( p = 0.725 \)), C4 (OR = 0.056, 95% CI: –0.102 to 0.215, \( p = 0.471 \)), C3 (OR = 0.009, 95% CI: –0.056 to 0.074, \( p = 0.776 \)) and dsDNA (OR = –2.285, 95% CI: –5.202 to 0.633, \( p = 0.119 \)).

**Discussion**

SLE is characterized by a large range of possible clinical and serological manifestations and a relapsing-remitting course [1–7]. Distinguishing disease activity from chronic damage and other comorbid diseases could alter its management [8–11]. On the other hand, there is no gold standard for measuring disease activity in SLE [31]. The use of a suitable activity index is desirable even in routine clinical practice as a way for guiding therapeutic decisions as objectively as possible [11].

We proposed the evaluation of Sβ2M/SCysC as a possible predictor of SLE activity in lupus nephritis since previous studies had shown increased Sβ2M in patients with active SLE [11–18]. It is of note that such previous findings could be influenced by GFR, so we included a GFR level adjustment, using the ratios Sβ2M/SCysC and Sβ2M/SCreat. Nevertheless, our results showed a weak correlation between SLE activity (using SLEDAI-2K criteria) and such indexes.

Interestingly Sβ2M showed a stronger correlation with SLEDAI-2K, as well as with the Sβ2M/SCreat index than with Sβ2M/SCysC, and the correlation between both serum indexes was moderate. In a multiple linear regression model using as reference the SLEDAI-2K, the Sβ2M/SCreat index was able to distinguish presence versus absence of activity as well as Sβ2M and urRBP.

This weak correlation between Sβ2M/SCysC and SLEDAI-2K could be explained by limitations of this activity criteria score as an outcome measure. For example, it is weighted only by perceived importance of an organ system rather than by the graded severity of manifestations within that organ system. In addition it evaluates the presence or absence of symptoms but not their improvement or worsening within a 10-day window [7, 8]. When we analyzed isolated Sβ2M levels, we found high levels of Sβ2M in this study population that indicated the GFR influence in its levels; so it was not a good index of activity in lupus nephritis. However, the good correlation observed between Sβ2M levels and SLEDAI-2K index could...
be due to the fact that S\(\beta\)2M is a good marker of SLE activity [12–14], and SLEDAI-2K evaluates global SLE activity and not only renal activity. On the other hand, we showed a moderate correlation between S\(\beta\)2M/SCreat and S\(\beta\)2M/SCysC. This finding is probably related to a better performance of the SCysC test, being able to detect renal dysfunction earlier than SCreat.

SCysC values showed a tendency to be elevated in our population, a pattern that is probably related to a GFR decline in this group of patients. We expected that S\(\beta\)2M/SCysC index could be a marker of SLE activity independently of the intensity of GFR impairment, since SCysC is considered as a potential candidate to replace SCreat in renal function evaluation, among other reasons for being less affected by muscle mass [32]. However, recent reports have shown substantial variability in the relationship between GFR and CysC among populations, suggesting that there may be differences in generation, tubular reabsorption, extrarenal elimination or interference of the use of steroid [20, 33, 34]. In fact, there are discrepancies among reports on the association between steroid use and SCysC concentration [35–40], which was not confirmed by us in a previous study too [41].

RBP is a tubular renal dysfunction marker that has been evaluated in patients with active lupus nephritis [42, 43]. In concordance with Sesso et al. [43], we have also shown that urRBP is a predictive marker of SLE activity.

It is of note that our study design has some limitations, such as the small sample and the lack of a gold standard method to evaluate GFR. Minimizing the latter, before the present study, we have evaluated SCysC performance versus a widely accepted GFR test, the plasma iohexol clearance. In such pilot study we observed a good correlation between SCysC and iohexol clearance in the evaluation of healthy voluntary individuals and patients with chronic kidney disease.

In a multivariate analysis, S\(\beta\)2M, S\(\beta\)2M/SCreat and urRBP were predictive factors for SLE activity (using SLEDAI-2K score); S\(\beta\)2M/SCysC and C4 have statistical association with those activity criteria, but not with dsDNA.

As many authors claim that SCysC is a better marker of renal function than SCreat, it would be expected that a serum S\(\beta\)2M/SCysC index could be a better indicator of renal activity than S\(\beta\)2M/SCreat, but in the present study it did not add relevant clinical information in the assessment of renal activity in SLE. Considering that SCysC has a higher sensitivity and lower specificity to detected loss of renal function when compared with SCreat, it is possible that S\(\beta\)2M/SCreat is a better marker for assessment of SLE activity in the lower ranges of GFR.

Further randomized studies are necessary to evaluate the S\(\beta\)2M/SCysC index in lupus nephritis, to avoid misinterpretation of this marker and define its usefulness in the evaluation of SLE patients.

Acknowledgement

This study was supported by CNPq (National Council for Scientific and Technological Development).
References

1. Hochberg M: Updating the American College Of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725–1730.
2. Petri M, Genovese M, Engle E, Hochberg M: Definition, incidence, and clinical description of flare in systemic lupus erythematosus. A prospective cohort study. Arthritis Rheum 1991;34:937–944.
3. Mirzayan MJ, Schmidt RE, Witte T: Prognostic parameters for flare in systemic lupus erythematosus. Rheumatology (Oxford) 2000;39:1316–1319.
4. Griffiths B, Mosca M, Gordon C: Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. Best Pract Res Clin Rheumatol 2005;19:685–708.
5. Gladman D, Goldsmith C, Urowitz M, et al: Cross-cultural validation and reliability of 3 disease activity indices in systemic lupus erythematosus. J Rheumatol 1992;19:608–611.
6. Symmons D, Coppack J, Bacon P, et al: Development and assessment of a computerized index of clinical disease activity in systemic lupus erythematosus. Members of the British Isles Lupus Assessment Group (BILAG). Q J Med 1988;69:927–937.
7. Bombardier C, Gladman D, Urowitz M, Caron D, Chang C: Derivation of the SLEDAI: A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992;35:630–640.
8. Gladman D, Ibanez D Urowitz M: Systematic lupus erythematosus disease activity index 2000. J Rheumatol 2002;29:288–291.
9. Liang MH, Socher SA, Larson MG, Schur PH: Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989;32:1107–1118.
10. Vitali C, Bencivelli W, Isenberg DA, et al: Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. II. Identification of the variables indicative of disease activity and their use in the development of an activity score. The European Consensus Study Group for Disease Activity in SLE. Clin Exp Rheumatol 1992;10:541–547.
11. Merril J, Buyon J: The role of biomarkers in the assessment of lupus. Best Pract Res Clin Rheumatol 2005;19:709–726.
12. Valencia ME, Molano J, Vazquez J, et al: Determination of beta-2-microglobulin levels in patients with systemic lupus erythematosus: correlation with clinical and biological parameters. Rev Clin Esp 1987;181:310–313.
13. Font J, Coca A, Molina R, et al: Serum beta 2-microglobulin as a marker of activity in systemic lupus erythematosus. Scand J Rheumatol 1986;15:201–205.
14. Evrin PE, Strom T: Beta 2-microglobulin and its binding activity in serum from patients with SLE. Ann Rheum Dis 1984;43:267–274.
15. Falus A, Meretey K, Glikmann G, et al: Beta2-microglobulin-containing IgG complexes in sera and synovial fluids of rheumatoid arthritis and systemic lupus erythematosus patients. Scand J Immunol 1981;13:25–34.
16. Tsai CY, Wu TH, Yu CL, Lu JY, Tsai YY: Increased excretions of beta2-microglobulin, IL-6, and IL-8 and decreased excretion of Tamm–Horsfall glycoprotein in urine of patients with active lupus nephritis. Nephron 2000;85:207–214.
17. Bokenkamp A, Van Wijk J, Lentze M, Stoffel-Wagner B: Effect of corticosteroid therapy on serum cystatin C and beta2-microglobulin concentrations. Clin Chem 2002;48:1123–1126.
18. Kim H-A, Jeon J-Y, Yoon JM, Suh CH: Beta 2-microglobulin can be a disease activity marker in systemic lupus erythematosus. Am J Med Sci 2010;339:337–340.
19. Laterza O, Price C, Scott M, Cystatin C: an improved estimator of glomerular filtration rate? Clin Chem 2002;48:699–707.
20. Herget-Rosenthal S, Bokenkamp A, Hofmann W: How to estimate GFR-serum creatinine, serum cystatin C or equations? Clin Biochem 2007;40:153–161.
21. Reed CH: Diagnostic applications of cystatin C. Br J Biomed Sci 2000;57:323–329.
22. Kos J, Stabuc B, Cimerman N, Brunner N: Serum cystatin C, a new marker of glomerular filtration rate, is increased during malignant progression. Clin Chem 1998;44:2556–2557.
23. Filler G, Bokenkamp A, Hofmann W, Le Bricon T, Martinez-Bru C, Grubb A: Cystatin C as a marker of GFR-history, indications, and future research. Clin Biochem 2005;38:1–8.
24. Mussap M, Plebani M: Biochemistry and clinical role of human cystatin C. Crit Rev Clin Lab Sci 2004;41:467–550.
25 Sjostrom P, Tidman M, Jones I: Determination of the production rate and non renal clearance of cystatin C and estimation of the glomerular filtration rate from the serum concentration of cystatin C in humans. Scand J Clin Lab Invest 2005;65:111–124.

26 Appel G, Silva F, Pirani C: Renal involvement in systemic lupus erythematosus (SLE): A study of 56 patients emphasizing histologic classification. Medicine 1978;75:371–410.

27 Pereira AB, Nishida SK, Vieira JG, et al: Monoclonal antibody-based immunoenzymometric assays of retinol-binding protein. Clin Chem 1993;39:472–476.

28 Erlandsen E, Randers E, Kristensen J: Reference intervals for serum cystatin C and serum creatinine in adults. Clin Chem Lab Med 1998;36:393–397.

29 Uhlmann E, Hock K, Issitt C, et al: Reference intervals for plasma cystatin C in healthy volunteers and renal patients, as measured by the Dade Behring BN II System and correlation with creatinine. Clin Chem 2001;47:2031–2033.

30 Levey A, Coresh J, Green T, et al: Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006;145:247–254.

31 El Hachmi M, Jadoul M, Lefebvre C, Depresseux G, Houssiau FA: Relapses of lupus nephritis: incidence, risk factors, serology and impact on outcome. Lupus 2003;12:692–696.

32 Rule AD, Bergstralh EJ, Slezak JM, Bergert J, Larson TS: Glomerular filtration rate estimated by cystatin C among different clinical presentations. Kidney Int 2006;69:399–405.

33 Stevens L, Coresh J, Schmid CH, et al: Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals, with CKD. Am J Kidney Dis 2008;51:395–406.

34 Madero M, SamaK M, Stevens L: Serum cystatin C as a marker of glomerular filtration rate. Curr Opin Neph Hyper 2006;15:610–616.

35 White C, Akbari A, Doucette S, et al: Effect of clinical variables and immunosuppression on serum cystatin C and beta-trace protein in kidney transplant recipients. Am J Kidney Dis 2009;54:922–930.

36 Risch L, Herklots R, Blumberg A, Huber A: Effects of glucocorticoid immunosuppression on serum cystatin C concentrations in renal transplant patients. Clin Chem 2001;47:2055–2059.

37 Risch L, Huber AR: Assessing glomerular filtration rate in renal transplant recipients by estimates derived from serum measurements of creatinine and cystatin C. Clin Chim Acta 2005;356:204–211.

38 Bjarnadottir M, Grubb A, Olfsson I: Promoter-mediated, dexamethasone-induced increase in cystatin C production by HeLa cells. Scand J Clin Lab Invest 1995;55:617–623.

39 Shlipak MG, Praught ML, Sarnak MJ: Update on cystatin C: new insights into the importance of mild kidney dysfunction. Curr Opin Nephrol Hypertens 2006;15:270–275.

40 White C, Akbari A, Doucette S, et al: Effect of clinical variables and immunosuppression on serum cystatin C and Beta trace protein in kidney transplant recipients. Am J Kidney Dis 2009;54:922–930.

41 Madureira M, Moscoso-Solorzano G, Nishida S, Mastroianni-Kirsztajn G: Are serum cystatin C levels influenced by steroid doses in nephritis patients? J Bras Nefrol 2011;33:306–312.

42 Mastroianni Kirsztajn G, Nishida S, Silva M, et al: Urinary retinol-binding protein as a prognostic marker in the treatment of nephrotic syndrome. Nephron 2000;86:109–114.

43 Sesso R, Rettori R, Nishida S, Ajzen H, Pereira AB: Assessment of lupus nephritis activity using urinary retinol-binding protein. Nephrol Dial Transplant 1994;9:367–371.